Published in J Heart Valve Dis on July 01, 2004
In situ elasticity modulation with dynamic substrates to direct cell phenotype. Biomaterials (2009) 2.41
The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol (2007) 2.18
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res (2005) 1.80
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol (2009) 1.32
Substrate properties influence calcification in valvular interstitial cell culture. J Heart Valve Dis (2008) 1.28
Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis (2011) 1.17
Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol (2009) 1.16
Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis (2010) 1.10
Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium. Arterioscler Thromb Vasc Biol (2009) 1.09
Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS One (2012) 1.03
Co-ordinating Notch, BMP, and TGF-β signaling during heart valve development. Cell Mol Life Sci (2012) 1.01
Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol (2014) 0.98
The long non-coding HOTAIR is modulated by cyclic stretch and WNT/β-CATENIN in human aortic valve cells and is a novel repressor of calcification genes. PLoS One (2014) 0.92
Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc Res (2013) 0.91
Transcriptional regulation of heart valve development and disease. Cardiovasc Pathol (2010) 0.88
Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS One (2013) 0.87
In vitro models of aortic valve calcification: solidifying a system. Cardiovasc Pathol (2014) 0.86
Pathogenesis of aortic stenosis: not just a matter of wear and tear. Am J Cardiovasc Dis (2011) 0.85
Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci (2012) 0.83
RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One (2011) 0.82
The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS. Curr Cardiol Rep (2010) 0.81
Aortic stenosis: An update. World J Cardiol (2010) 0.81
Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway. Cardiovasc Diabetol (2014) 0.78
One problem two issues! Left ventricular systolic and diastolic dysfunction in aortic stenosis. Ann Transl Med (2014) 0.75
Valve Calcification in Aortic Stenosis: Etiology and Diagnostic Imaging Techniques. Biomed Res Int (2017) 0.75
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 4.23
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J (2006) 2.59
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation (2013) 2.48
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J (2006) 2.28
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol (2004) 2.23
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation (2005) 2.20
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation (2011) 2.17
Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol (2003) 2.14
Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol (2007) 2.09
Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg (2008) 2.04
A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J (2006) 2.01
Is arterial pulse contour analysis using Nexfin a new option in the noninvasive measurement of cardiac output?--A pilot study. J Cardiothorac Vasc Anesth (2012) 2.00
Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat (2014) 1.98
Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm (2009) 1.92
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res (2005) 1.81
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol (2007) 1.79
Valproate-associated coagulopathies are frequent and variable in children. Epilepsia (2006) 1.79
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78
Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg (2008) 1.76
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Early repolarization pattern is associated with ventricular fibrillation in patients with acute myocardial infarction. Heart Rhythm (2012) 1.71
Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 1.68
Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol (2004) 1.67
Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis (2006) 1.65
Are women with severely symptomatic brugada syndrome different from men? J Cardiovasc Electrophysiol (2008) 1.62
Noninvasive determination of cardiac output by the inert-gas-rebreathing method--comparison with cardiovascular magnetic resonance imaging. Cardiology (2009) 1.56
Reevaluation of direct true lumen cannulation in surgery for acute type A aortic dissection. Ann Thorac Surg (2009) 1.53
Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J (2004) 1.52
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost (2012) 1.51
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail (2013) 1.50
Takotsubo cardiomyopathy (acute left ventricular apical ballooning syndrome) occurring in the intensive care unit. Intensive Care Med (2006) 1.50
Coronary computed tomography and triple rule out CT in patients with acute chest pain and an intermediate cardiac risk profile. Part 1: impact on patient management. Eur J Radiol (2012) 1.50
Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis (2003) 1.49
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J (2006) 1.48
Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace (2009) 1.47
Overestimation of aortic valve replacement risk by EuroSCORE: implications for percutaneous valve replacement. Eur Heart J (2008) 1.46
Cardiovascular magnetic resonance findings in typical versus atypical forms of the acute apical ballooning syndrome (Takotsubo cardiomyopathy). Int J Cardiol (2006) 1.46
Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase. Crit Care Med (2004) 1.46
Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest. J Thorac Cardiovasc Surg (2003) 1.44
Influence of different implantation techniques on AV valve competence after orthotopic heart transplantation. Eur J Cardiothorac Surg (2005) 1.43
Sudden death: do cytokines and prothrombotic peptides contribute to the occurrence of ventricular fibrillation during acute myocardial infarction? Int J Cardiol (2009) 1.43
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
A new computer model of mitral valve hemodynamics during ventricular filling. Eur J Cardiothorac Surg (2004) 1.43
Adaptation of the right ventricle to an increased afterload in the chronically volume overloaded heart. Ann Thorac Surg (2006) 1.42
Multiple wavelets, rotors, and snakes in atrial fibrillation--a computer simulation study. J Electrocardiol (2007) 1.42
Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm (2008) 1.42
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J (2012) 1.41
Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization--prospective evaluation at diffusion-weighted MR imaging. Radiology (2005) 1.40
Impact of functional, morphological and clinical parameters on epicardial adipose tissue in patients with coronary artery disease. Circ J (2012) 1.39
2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Rev Esp Cardiol (Engl Ed) (2016) 1.39
Recommendations for improving the quality of the interdisciplinary medical care of grown-ups with congenital heart disease (GUCH). Int J Cardiol (2010) 1.39